Publications by authors named "A S Swern"
Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody) have limited treatment options and there is no standard of care. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, demonstrated efficacy in triple-class exposed RRMM patients in the KarMMa trial (NCT03361748). In this retrospective study (KarMMa-RW), patient-level data from triple-class exposed RRMM patients were merged into a single data model and compared with KarMMa using trimmed stabilized inverse probability of treatment weighting.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the frequency of ring sideroblasts (RS) and SF3B1 gene mutation testing in lower-risk myelodysplastic syndromes (MDS) before and after the 2016 WHO classification criteria were published.
- Out of 489 LR-MDS patients, a high percentage underwent RS assessment, but a low percentage of those with less than 15% RS were tested for SF3B1 mutations, indicating a gap in testing practices.
- No significant change in RS assessment rates was observed post-publication of WHO guidelines, highlighting a need for improved education on the importance of genetic testing in these patients.
Health-related quality of life (HRQoL) in patients with chronic lymphocytic leukemia (CLL) is important in guiding treatment decisions. However, the impact of CLL treatment initiation on HRQoL is unclear. We assessed HRQoL using the FACT-Leu and EQ-5D-3L questionnaires in the Connect CLL Registry, a large, US-based, multicenter, prospective observational study of CLL patients enrolled between 2010 and 2014, prior to the introduction of novel therapies.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on diagnostic and molecular genetic testing for older patients with acute myeloid leukemia (AML), analyzing data from 565 patients aged 55 and older enrolled in a disease registry in the U.S.
- It found that the majority of patients had their bone marrow characteristics assessed, with high rates of testing using flow cytometry and karyotyping; however, molecular testing was performed more in academic settings compared to community/government sites.
- The research highlights a significant rise in molecular testing patterns since 2016, aiming to reveal gaps in current practices that could enhance guidelines for diagnosing AML patients.
Background: Patient registries are organized systems that use observational methods to collect uniform data on specified outcomes in a population defined by a particular disease, condition, or exposure. Data collected in registries often coincide with data that could support clinical trials. Integrating clinical trials within registries to create registry-embedded clinical trials offers opportunities to reduce duplicative data collection, identify and recruit patients more efficiently, decrease time to database lock, accelerate time to regulatory decision-making, and reduce clinical trial costs.
View Article and Find Full Text PDF